2315 related articles for article (PubMed ID: 22541366)
41. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
[TBL] [Abstract][Full Text] [Related]
42. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
43. Drug therapy of dementia in elderly patients. A review.
Olsen CE; Poulsen HD; Lublin HK
Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103
[TBL] [Abstract][Full Text] [Related]
44. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
45. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
[TBL] [Abstract][Full Text] [Related]
46. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
47. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
[TBL] [Abstract][Full Text] [Related]
48. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.
Clarke A; Pulikottil-Jacob R; Grove A; Freeman K; Mistry H; Tsertsvadze A; Connock M; Court R; Kandala NB; Costa M; Suri G; Metcalfe D; Crowther M; Morrow S; Johnson S; Sutcliffe P
Health Technol Assess; 2015 Jan; 19(10):1-668, vii-viii. PubMed ID: 25634033
[TBL] [Abstract][Full Text] [Related]
49. Evidence-based pharmacotherapy of Alzheimer's disease.
Evans JG; Wilcock G; Birks J
Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
[TBL] [Abstract][Full Text] [Related]
50. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
51. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Ehret MJ; Chamberlin KW
Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
[TBL] [Abstract][Full Text] [Related]
52. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
53. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
54. Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes.
May BH; Feng M; Hyde AJ; Hügel H; Chang SY; Dong L; Guo X; Zhang AL; Lu C; Xue CC
Int J Geriatr Psychiatry; 2018 Mar; 33(3):449-458. PubMed ID: 29239495
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M; Eap CB
Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
[TBL] [Abstract][Full Text] [Related]
56. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Getsios D; Blume S; Ishak KJ; Maclaine GD
Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
[TBL] [Abstract][Full Text] [Related]
57. The effects of different acetylcholinesterase inhibitors on EEG patterns in patients with Alzheimer's disease: A systematic review.
Arjmandi-Rad S; Vestergaard Nieland JD; Goozee KG; Vaseghi S
Neurol Sci; 2024 Feb; 45(2):417-430. PubMed ID: 37843690
[TBL] [Abstract][Full Text] [Related]
58. Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer's Disease in the United States: A Cost-Effectiveness Analysis.
Yunusa I; Alsahali S; Rane A; Eguale T
J Alzheimers Dis Rep; 2021; 5(1):705-713. PubMed ID: 34755044
[TBL] [Abstract][Full Text] [Related]
59. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
Truter I
Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
[TBL] [Abstract][Full Text] [Related]
60. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
